{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:08:27Z","timestamp":1793419707842,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.euo.2024.10.003","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T11:32:13Z","timestamp":1729078333000},"page":"681-688","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Cost-effectiveness Analysis in the New Era of Treatment Strategies in Metastatic Urothelial Carcinoma Based on Checkmate-901 and EV302\/Keynote-A39"],"prefix":"10.1016","volume":"8","author":[{"given":"Constantin","family":"Rieger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Schl\u00fcchtermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enno","family":"Storz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Weiten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Bach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Heidenreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2024.10.003_b0005","first-page":"199","article-title":"Cisplatin: impact of a new anticancer agent on current therapeutic strategies","volume":"1","author":"Rozencweig","year":"1981","journal-title":"Anticancer Res"},{"key":"10.1016\/j.euo.2024.10.003_b0010","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.22.01792","article-title":"Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN Bladder 100 trial after \u22652 years of follow-up","volume":"41","author":"Powles","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.10.003_b0015","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.10.003_b0020","unstructured":"European Association of Urology. Muscle-invasive and metastatic bladder cancer, full test guideline. 2024. https:\/\/uroweb.org\/guidelines\/muscle-invasive-and-metastatic-bladder-cancer\/chapter\/disease-management."},{"key":"10.1016\/j.euo.2024.10.003_b0025","article-title":"Nivolumab plus gemcitabin-cisplatin vs gemcitabin-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: results from the phase III CheckMate 901 trial","author":"Van der Heijden","year":"2013","journal-title":"ESMO Congress"},{"key":"10.1016\/j.euo.2024.10.003_b0030","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s40273-014-0194-2","article-title":"The health economics of bladder cancer: an updated review of the published literature","volume":"32","author":"Yeung","year":"2014","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.euo.2024.10.003_b0035","unstructured":"Surveillance, Epidemiology, and End Results Program. Cancer stat facts: bladder cancer. https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html."},{"key":"10.1016\/j.euo.2024.10.003_b0040","doi-asserted-by":"crossref","unstructured":"Contieri R, Martini A, Mertens LS, et al. The financial burden of guideline-recommended cancer medications for meta- static urothelial carcinoma. Eur Urol Focus. In press. https:\/\/doi.org\/10.1016\/j.euf.2023.12.002.","DOI":"10.1016\/j.euf.2023.12.002"},{"key":"10.1016\/j.euo.2024.10.003_b0045","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1080\/13696998.2020.1715414","article-title":"Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States","volume":"23","author":"Haddad","year":"2020","journal-title":"J Med Econ"},{"key":"10.1016\/j.euo.2024.10.003_b0050","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.10.003_b0055","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.8787","article-title":"Cost-effectiveness of nivolumab-ipilimumab combination therapy for the treatment of advanced non-small cell lung cancer","volume":"4","author":"Courtney","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.euo.2024.10.003_b0060","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","article-title":"Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance","volume":"29","author":"Kl\u00fcmper","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"4-suppl","key":"10.1016\/j.euo.2024.10.003_b0065","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1200\/JCO.2024.42.4_suppl.673","article-title":"Occurrence of NECTIN4 amplification in solid tumors and enfortumab vedotin response in metastatic urothelial cancer","volume":"42","author":"Kl\u00fcmper","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.10.003_b0070","first-page":"1310","article-title":"Increasing divergence in drug prices between the United States and Germany after implementation of comparative effectiveness analysis and collective price negotiations","volume":"25","author":"Berkemeier","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.euo.2024.10.003_b0075","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1097\/JU.0000000000001515","article-title":"Cost-effectiveness analysis of pembrolizumab for bacillus Calmette-Gu\u00e9rin-unresponsive carcinoma in situ of the bladder","volume":"205","author":"Wymer","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.10.003_b0080","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/bju.16332","article-title":"Cost-effectiveness analysis of different treatment modalities in BCG -unresponsive NMIBC","volume":"134","author":"Rieger","year":"2024","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2024.10.003_b0085","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.eururo.2018.03.006","article-title":"Cost-effectiveness of pembrolizumab in second-line advanced bladder cancer","volume":"74","author":"Sarfaty","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.10.003_b0090","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.euo.2018.09.009","article-title":"Cost-effectiveness of pembrolizumab for patients with advanced, unresectable, or metastatic urothelial cancer ineligible for cisplatin-based therapy","volume":"2","author":"Patterson","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2024.10.003_b0095","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000536321","article-title":"An empirical survey on the adaption of neoadjuvant chemotherapy in bladder cancer","volume":"108","author":"Reike","year":"2024","journal-title":"Urol Int"},{"key":"10.1016\/j.euo.2024.10.003_b0100","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.urolonc.2014.05.001","article-title":"Cost-effectiveness of neoadjuvant chemotherapy before radical cystectomy for muscle-invasive bladder cancer","volume":"32","author":"Stevenson","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2024.10.003_b0105","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.eururo.2018.10.055","article-title":"Cost-effectiveness analysis of active surveillance strategies for men with low-risk prostate cancer","volume":"75","author":"Sathianathen","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.10.003_b0110","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1001\/jama.2022.9265","article-title":"Effect of electronic symptom monitoring on patient-reported outcomes among patients with metastatic cancer: a randomized clinical trial","volume":"327","author":"Basch","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.euo.2024.10.003_b0115","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1089\/jpm.2019.0342","article-title":"Mobile health technologies for continuous monitoring of cancer patients in palliative care aiming to predict health status deterioration: a feasibility study","volume":"23","author":"Pavic","year":"2020","journal-title":"J Palliat Med"},{"key":"10.1016\/j.euo.2024.10.003_b0120","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211068733","article-title":"Cost-effectiveness of enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"14","author":"Wu","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.euo.2024.10.003_b0125","unstructured":"Micromedex Solutions. https:\/\/www.micromedexsolutions.com\/."}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124002311?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124002311?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T16:55:18Z","timestamp":1748451318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931124002311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2588931124002311"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2024.10.003","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness Analysis in the New Era of Treatment Strategies in Metastatic Urothelial Carcinoma Based on Checkmate-901 and EV302\/Keynote-A39","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2024.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}